PACB Pacific Biosciences of California Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PACB

Price (delayed)

$1.15

Market cap

$357.46M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$1B

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 16
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 27

PacBio is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies ...

Highlights
The EPS has soared by 76% YoY
The revenue has increased by 2% YoY
PACB's net income has soared by 75% YoY but it is down by 2.2% QoQ
Pacific Biosciences of California's gross profit has surged by 74% YoY but it has decreased by 3.4% QoQ
The company's equity has shrunk by 154% YoY
The quick ratio has contracted by 33% YoY and by 16% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.pacb.com
Peers: ILMN GE TMO

Key stats

What are the main financial stats of PACB

PACB stock price

How has the Pacific Biosciences of California stock price performed over time
Intraday
3.6%
1 week
-1.29%
1 month
-22.82%
1 year
-10.16%
YTD
-38.5%
QTD
-31.55%

Financial performance

How have Pacific Biosciences of California's revenue and profit performed over time
Revenue
$159.27M
Gross profit
$57.95M
Operating income
-$133.04M
Net income
-$131.39M
Gross margin
36.4%
Net margin
-82.5%
PACB's operating margin has surged by 82% year-on-year
The company's operating income has surged by 81% YoY
The net margin has soared by 76% year-on-year but it is down by 2.7% since the previous quarter
PACB's net income has soared by 75% YoY but it is down by 2.2% QoQ

Price vs fundamentals

How does PACB's price correlate with its fundamentals

Growth

What is Pacific Biosciences of California's growth rate over time

Valuation

What is Pacific Biosciences of California stock price valuation
P/E
N/A
P/B
N/A
P/S
2.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.29
The EPS has soared by 76% YoY
The company's equity has shrunk by 154% YoY
The price to sales (P/S) is 79% lower than the 5-year quarterly average of 10.9 and 25% lower than the last 4 quarters average of 3.0
The revenue has increased by 2% YoY

Efficiency

How efficient is Pacific Biosciences of California business performance
The ROS has soared by 77% YoY but it has contracted by 2.5% from the previous quarter
The company's return on invested capital has surged by 73% YoY but it fell by 3.4% QoQ
PACB's ROA has soared by 65% YoY but it is down by 4.3% from the previous quarter

Dividends

What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PACB.

Financial health

How did Pacific Biosciences of California financials performed over time
The company's total assets is 4.2% lower than its total liabilities
The quick ratio has contracted by 33% YoY and by 16% from the previous quarter
The company's current ratio fell by 29% YoY and by 13% QoQ
The company's equity has shrunk by 154% YoY
The company's debt to equity has shrunk by 107% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.